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Abstract
Background: In cystic fibrosis, highly variable glucose tolerance is suspected. However, no study provided within-patient
coefficients of variation. The main objective of this short report was to evaluate within-patient variability of oral glucose
tolerance.
Methods: In total, 4,643 standardized oral glucose tolerance tests of 1,128 cystic fibrosis patients (median age at first test:
15.5 [11.5; 21.5] years, 48.8% females) were studied. Patients included were clinically stable, non-pregnant, and had at least
two oral glucose tolerance tests, with no prior lung transplantation or systemic steroid therapy. Transition frequency from
any one test to the subsequent test was analyzed and within-patient coefficients of variation were calculated for fasting and
two hour blood glucose values. All statistical analysis was implemented with SAS 9.4.
Results: A diabetic glucose tolerance was confirmed in 41.2% by the subsequent test. A regression to normal glucose
tolerance at the subsequent test was observed in 21.7% and to impaired fasting glucose, impaired glucose tolerance or
both in 15.2%, 12.0% or 9.9%. The average within-patient coefficient of variation for fasting blood glucose was 11.1% and
for two hour blood glucose 25.3%.
Conclusion: In the cystic fibrosis patients studied, a highly variable glucose tolerance was observed. Compared to the
general population, variability of two hour blood glucose was 1.5 to 1.8-fold higher.
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Introduction
Cystic fibrosis (CF) is a life-limiting autosomal recessive illness
occurring in about one of 2,500 newborns in Europe. As the life
expectancy for CF patients has increased due to earlier diagnosis
and improved care, CF-related comorbidities became more
frequent over the last decades. A growing comorbidity with
impact on the course of CF is cystic fibrosis-related diabetes
(CFRD). The latest comprehensive guidelines for CFRD recom-
mend yearly screening for abnormal glucose metabolism by oral
glucose tolerance test (OGTT) in CF patients aged $10 years [1].
A small study suspected that CF patients have a high variation in
glucose tolerance over time [2].
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Therefore, we aimed to investigate in this short report the
variability of glucose tolerance in a large cohort of CF patients. For
the first time, a within-patient coefficient of variation (CV) for 2-
hour blood glucose was calculated in CF.
Materials and Methods
Ethics statement
The ethical committees of Ulm University and Hannover
Medical School approved the study, and patients or their parents
provided written informed consent.
Study subjects
Between 2001 and 2010, 1,778 CF patients aged 10 years or
older were screened serially by OGTT in a multicenter screening
program carried out by 43 German/Austrian specialized centers
(Trial No. NCT00662714). All patients had a physician-based
diagnosis of CF according to the latest German guidelines [3].
OGTTs were performed and interpreted in line with recommen-
dations of the World Health Organization modified by the
American Diabetes Association as described in detail previously
[4,5].
In total, 5,765 OGTTs among clinically stable CF patients were
carried out until the end of the study (Figure 1). As mentioned in
reference [4], all patients screened had to be without symptoms of
acute infections or exacerbations of chronic infections and should
not have a reduced carbohydrate intake. Moreover, patients with
respiratory failure (FEV1,40%) or with enteral tube feeding were
excluded. In case of a confirmed diagnosis of CFRD or the use of
anti-hyperglycemic treatment, patients were also excluded from
screening.
For the present analysis, only OGTTs of non-pregnant patients
with no prior systemic steroid therapy or lung transplantation were
considered (Figure 1). If patients awaited lung transplantation,
OGTTs were also excluded. Furthermore, at least two OGTTs
had to be performed per patient (Figure 1). The final study
population comprised 4,643 OGTTs of 1,128 CF patients. For
each patient included, test results were classified as normal glucose
tolerance (NGT), impaired fasting glucose (IFG), impaired glucose
tolerance (IGT), IFG and IGT combined, or diabetic glucose
tolerance (DGT). The detailed cut-offs are described in reference
[4]. As there are some CF patients with isolated IFG [4] and the
pathophysiology between IFG and IGT is at least in part different
[6], we introduced an IFG group in this analysis. CFRD was
defined as a diabetic OGTT confirmed by a consecutive OGTT in
the DGT range [1]. Body mass index standard deviation score
(BMI-SDS) was calculated using data from the German Health
Interview and Examination Survey for Children and Adolescents
(KiGGS study, [7]) as national reference. The KiGGS study was
used as a reference in a number of previous publications by our
group to calculate BMI-SDS in CF patients [4,8,9] and is the best
currently available reference data for healthy German children.
Data to calculate BMI-SDS on the basis of CF-specific anthro-
pometric reference percentiles are currently not available.
Statistical analysis
To analyze the variation in glucose tolerance, transition
frequency from any one test to the subsequent test was studied.
As there is no subsequent test for the last test in each patient, 3,515
pairs of consecutive OGTTs were available in the study
population (the number of OGTT pairs therefore equals the total
number of OGTTs minus the number of patients). For each pair
of OGTTs, the first test was categorized in one of the five glucose
Figure 1. Selection of study population. Abbreviations: CF cystic fibrosis, OGTT oral glucose tolerance test.
doi:10.1371/journal.pone.0112578.g001
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tolerance classes (NGT, IFG only, IGT only, IFG+IGT, DGT)
and the percentage of subsequent test results was calculated.
Moreover, the variation in glucose tolerance is depicted in three
individual patients who had seven consecutive OGTTs with at
least one diabetic result. To assess the degree of variability of
serially measured fasting and 2-hour blood glucose values in CF
patients, within-patient CVs (defined as ratio between within-
subject standard deviation and mean) were calculated and
compared to the general population. CVs were calculated as they
are normalized measures of the variability and independent of the
mean level.
To evaluate gender or age differences in the deterioration of
glucose tolerance from test to test, a logistic mixed regression
model was applied. Deterioration of glucose metabolism was
defined as worsening of glucose tolerance in a subsequent test
compared to the pretest or as confirmation of a diabetic OGTT.
Sex and age were entered as independent fixed effects. Age was
categorized as 10–,15 years, 15–,20 years and $20 years. To
account for repeated OGTTs per patient, random effects with
first-order autoregressive covariance structure were used. Results
are given as odds ratios (OR) with lower and upper confidence
limit (CL).
Statistical analyses were performed with SAS 9.4. The level of
significance was set at 0.05. To compare demographics between
patients included and excluded, Kruskal-Wallis test was applied
for continuous parameters and x2-test for dichotomous parame-
ters.
Results
48.8% of patients included were female and 28.9% were .20
years. Median [Q1;Q3] (mean6SD) age at first OGTT was 15.5
[11.5; 21.5] (18.068.4) years and at last OGTT 18.6 [15.3; 25.4]
(21.368.5) years. At baseline OGTT, the youngest patient aged
10.0 years and the oldest patient 63.9 years. On average, median
(mean) duration between two consecutive OGTTs was 1.0 [0.7;
1.2] (1.160.7) year. A diabetic OGTT was repeated within a
median (mean) time of 6.9 [4.9; 12.9] (9.166.2) weeks. As
published previously [4], the median duration between two
consecutive OGTTs in the DGT range (confirmed diagnosis of
CFRD) was 8.1 [5.1; 27.9] weeks. All patients with suspected
CFRD (i.e. one OGTT in the DGT range) at the end of the study
were followed-up outside the context of the screening study. Each
patient with a confirmed diagnosis of CFRD was invited to
participate in a randomized controlled trial investigating the use of
repaglinide in comparison to insulin therapy. CFRD patients not
participating in the clinical trial received insulin therapy and CF-
specific nutritional counseling as recommended by guidelines.
Baseline characteristics of the 650 patients excluded are
depicted in table 1. Excluded patients were older and had on
average a lower BMI-SDS.
Figure 2 displays the transition frequency from any one test to a
subsequent test. For example, an OGTT in the DGT range was
confirmed in 41.2% by the subsequent test.
Figure 2. Transition from any one test to a subsequent test. In
total, 3,515 pairs of consecutive OGTTs are summarized. For each pair,
the first test was categorized in one of the five glucose tolerance classes
(NGT, IFG only, IGT only, IFG+IGT, DGT). The figure shows the
percentage of subsequent test results for each glucose tolerance
category. The number in parentheses indicates the number of OGTTs
available for analysis. Abbreviations: NGT normal glucose tolerance, IFG
impaired fasting glucose, IGT impaired glucose tolerance, DGT diabetic
glucose tolerance, OGTT oral glucose tolerance test.
doi:10.1371/journal.pone.0112578.g002
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Until the end of the screening study, a total of 136 CF patients
revealed a confirmed diagnosis of CFRD i.e. two consecutive
OGTTs revealing DGT. Despite the fact that two consecutive
OGTTs in the DGT range are sufficient to diagnose CFRD, 54
out of the 136 patients had additional OGTTs. In 42.6% (n= 23)
of patients, all subsequent tests were diabetic. In 20.4% (n= 11) of
cases, at least one of the subsequent tests revealed NGT.
Figure 3 indicates that independent of age, glucose tolerance
varied highly from test to test in three individual patients.
Overall, in CF patients the average within-patient CV for
fasting blood glucose values was 11.1% and for 2-hour blood
glucose 25.3%. Analyzing patients with (n = 339) and without
(n = 789) at least one OGTT in the DGT range separately,
patients without an OGTT in the diabetic range had lower CVs
for both fasting and 2-hour blood glucose values (fasting: 8.9 vs.
16.1%, p,0.001; 2-hour: 22.2 vs. 32.4%, p,0.001).
Logistic regression analysis revealed for girls a 1.18-fold [lower
CL: 1.03; upper CL: 1.36] higher risk for the deterioration of
Table 1. Demographics of patients included and patients excluded at baseline OGTT.
Patients included Patients excluded p-value
Number, n 1,128 650 -
Age, years 15.5 [11.5; 21.5] (18.068.4) 17.4 [12.3; 25.2] (20.069.3) ,0.001
Female sex, % 48.8 45.1 NS
Weight, kg 47.8 [34.5; 57.8] (47.8615.4) 50.2 [35.5; 59.0] (49.0615.2) 0.04
Height, cm 160.0 [145.6; 170.0] (157.8615.6) 162.0 [147.0; 172.0] (159.8615.9) 0.008
BMI, kg/m2 18.4 [16.2; 20.4] (18.663.3) 18.6 [16.2; 20.7] (18.763.3) NS
BMI-SDS –0.76 [–1.42;–0.11] (–0.8061.08) –0.87 [–1.65;–0.18] (–0.9961.26) 0.005
Data are given as median with quartiles (mean with standard deviation) or as percentage. Abbreviations: BMI body mass index, SDS standard deviation score, NS not
significant.
doi:10.1371/journal.pone.0112578.t001
Figure 3. Variation of glucose tolerance in three patients of different age. Each patient had seven consecutive OGTTs with at least one
diabetic result. Abbreviations: DGT diabetic glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, NGT normal glucose
tolerance, OGTT oral glucose tolerance test.
doi:10.1371/journal.pone.0112578.g003
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glucose tolerance compared to boys (p = 0.015). In addition,
patients aged 15–,20 years (OR: 1.23 [1.04; 1.47], p = 0.019) or
$20 years (OR: 1.22 [1.03; 1.44], p= 0.024) had a higher risk
than patients aged 10–,15 years. In 15 to ,20 year old patients,
risk was comparable to patients aged $20 years (OR: 1.01 [0.86;
1.19], p= 0.867).
Analyzing the influence of sex in the subgroup of older patients
(.20 years at baseline OGTT; n= 326 patients with 1,276
OGTTs), revealed also an increased risk in females compared to
males, even though the influence was no longer significant due to
the lower number of patients studied (OR: 1.23 [0.92; 1.63],
p = 0.162).
Discussion
Our analysis among asymptomatic CF patients revealed a high
variability in glucose tolerance over time, even though patients without
DGT seem to be more stable with respect to glucose tolerance.
Compared to the general population [10–12], overall within-patient
variability of 2-hour blood glucose is 1.5 to 1.8-fold higher in CF. The
NHANES III Second Examination revealed a within-patient CV of
16.6% for 2-hour blood glucose [12] and the Hoorn study of 16.7%
[11]. In a general practice [10], a within-patient CV of 14.3% was
observed. Fluctuating levels of insulin resistance due to acute and
chronic infections or CF-related inflammatory cytokines may explain
the highly variable glucose tolerance in CF.
The fluctuation in glucose tolerance observed in this study
implicates regular control of glucose metabolism in CF. Future
guidelines should provide recommendations regarding an ade-
quate time frame for repeating OGTTs in patients with abnormal
glucose tolerance as well as for the confirmation interval of a
diabetic test result. As outlined by the study protocol and described
previously [4], a diabetic OGTT had to be repeated within 4 to 6
weeks in the present study and an OGTT revealing IFG or IGT
after 6 months. According to guidelines, all patients with a
confirmed CFRD diagnosis or with a diabetic OGTT and classical
symptoms of diabetes should receive insulin treatment immedi-
ately [1]. Oral antidiabetic agents are not advised until sufficient
data become available regarding their efficiency.
Reasons for performing additional OGTTs in patients with
already confirmed CFRD are unknown. Maybe patients requested
an additional OGTT in the context of intensifying therapy.
Especially, asymptomatic CF patients often have problems starting
insulin treatment besides numerous CF-related therapies. Another
possibility might be that patients with a confirmed CFRD diagnosis
were not totally clinically stable at the time of the confirmation test
and the medical team therefore decided to repeat the test at a later
time point. As OGTT results depend also on the supplementation of
pancreatic enzymes, the medical team may have repeated the
confirmation test after adjusting pancreatic enzyme substitution.
Although the OGTT revealed a high degree of within-patient
variance in CF, it is the best screening tool for abnormalities in
glucose tolerance currently available. Fasting plasma glucose,
hemoglobin A1c or other classical methods applicable for type 1 or
type 2 diabetes are not recommended in CF [1]. In the future,
continuous glucose monitoring or standardized test meals might be
a useful alternative to OGTT. However, there are no reference
values for continuous glucose monitoring so far. To minimize the
variability of OGTTs in CF patients, CF-adapted standardization
might be one possibility. At the moment, criteria for the
performance and interpretation of OGTT are identical to other
diabetes types. However, pancreatic enzyme substitution and the
grade of inflammation (e.g. C-reactive protein measurement)
should be considered before performing an OGTT in CF, and
when interpreting OGTT results. More advanced interpretation
criteria that take into account dynamics in oral glucose challenge
in CF patients might be appropriate. As CFRD is less common
compared to the more frequent type 1 or type 2 diabetes, other
measures of ß-cell function (e.g. C-peptide) or calculation of
indices for insulin secretion and sensitivity might be practicable in
clinical settings that may result in better assessment of glucose
tolerance in CF patients.
The higher risk for deterioration of glucose tolerance in girls
confirms previous studies indicating an earlier onset and a higher
prevalence of CFRD in females [4,13,14]. The lower risk in
patients younger than 15 years compared to older patients might
be explained by the rare occurrence of CFRD in patients ,10
years and the increasing prevalence of abnormal glucose tolerance
with age [4,15,16].
Selection biases might be one limitation of the present study.
Not all centers or CF patients participated, although all German/
Austrian medical facilities providing care for CF patients were
invited for participation in written form. Moreover, some CF-
related therapies (e.g. steroids, lung transplantation) led to
exclusion of patients and the complexity of CF itself made study
participation often difficult. The higher age and the lower BMI-
SDS of patients excluded may point to a more severe progression
of the disease compared to patients included. Exclusion criterion
for the majority of the 650 patients not analyzed was the
availability of solely one OGTT. This might be due to termination
of the study or occurrence of exclusion criteria after the first
OGTT. Moreover, each patient could withdraw from the study at
any time.
In summary, in the asymptomatic CF patients studied, one
diabetic OGTT seems not sufficient to diagnose CFRD due to the
existing high variability of glucose tolerance. A normal glucose
tolerance after a confirmed CFRD diagnosis (i.e. two consecutive
OGTTs revealing DGT) cannot be excluded. Despite improve-
ment of glucose tolerance, these patients are classified as diabetic
[1], although this labelling may be contra-intuitive for patients and
physicians. It is still a debate whether solely a persistently diabetic
glucose tolerance is associated with an increased risk of clinical
decline in CF or even a pre-diabetic condition.
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